{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:31:57Z","timestamp":1784136717667,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.rpsm.2016.09.003","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:16:09Z","timestamp":1481069769000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["S\u00edndrome metab\u00f3lico y antipsic\u00f3ticos at\u00edpicos. Posibilidad de predicci\u00f3n y control"],"prefix":"10.1016","volume":"10","author":[{"given":"Clara M.","family":"Franch Pato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Molina Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Franch Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2016.09.003_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.publhealth.012809.103701","article-title":"Confronting a neglected epidemic: Tobacco cessation for persons with mental illnesses and substance abuse problems","volume":"31","author":"Schroeder","year":"2010","journal-title":"Annu Rev Public Health."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0135","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1888-9891(09)70714-1","article-title":"Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave","volume":"2","author":"De Hert","year":"2009","journal-title":"Rev Psiquiatr Salud Ment (Barc)."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0150","first-page":"251","article-title":"Consenso sobre la salud f\u00edsica del paciente con esquizofrenia de las Sociedades Espa\u00f1olas de Psiquiatr\u00eda y de Psiquiatr\u00eda Biol\u00f3gica","volume":"36","author":"S\u00e1iz Ruiz","year":"2008","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.rpsm.2016.09.003_bib0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1888-9891(08)72513-8","article-title":"Consenso Espa\u00f1ol de Salud F\u00edsica del Paciente con Trastorno Bipolar","volume":"1","author":"Bobes","year":"2008","journal-title":"Rev Psiquiatr Salud Ment (Barc)."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0160","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002018-200629040-00002","article-title":"Long-term treatment with atypical antipsychotics and the risk of weight gain. A literature analysis","volume":"29","author":"Gentile","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0170","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/070674370304801008","article-title":"Risk of weight gain associated with antipsychotic treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia","volume":"48","author":"McIntyre","year":"2003","journal-title":"Can J Psychiatry."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in fist-episode patients with schizophrenia: A retrospective chat review","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0195","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0976-500X.114596","article-title":"Metabolic syndrome in schizophrenia: Differences between antipsychotic-naive and treated patients","volume":"4","author":"Chadda","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.rpsm.2016.09.003_bib0200","first-page":"174","article-title":"The metabolic syndrome and schizophrenia: A comorbidity or an association","volume":"4","author":"Khalil","year":"2013","journal-title":"J Pharmacol Pharmacother."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0255","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-0035-1569416","article-title":"A diet and fitness program similarly affects weight reduction in schizophrenia patients treated with typical or atypical medications","volume":"49","author":"Amiaz","year":"2016","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0205","doi-asserted-by":"crossref","first-page":"e0149209","DOI":"10.1371\/journal.pone.0149209","article-title":"Metabolic syndrome in South African patients with severe mental illness: Prevalence and associated risk factors","volume":"11","author":"Saloojee","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/pcn.12110","article-title":"Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia","volume":"68","author":"Cort\u00e9s","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.rpsm.2016.09.003_bib0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.64719\/pb.4081","article-title":"Early predictors of weight gain risk during treatment with olanzapine: Analysis of pooled data from 58 clinical trials","volume":"42","author":"Lipkovich","year":"2009","journal-title":"Psychopharmacol Bull."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1467-789X.2009.00589.x","article-title":"Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications","volume":"10","author":"Gentile","year":"2009","journal-title":"Obes Rev."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0225","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/er.2008-0024","article-title":"The metabolic syndrome","volume":"29","author":"Cornier","year":"2008","journal-title":"Endocr Rev."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1755-5949.2011.00240.x","article-title":"Metabolic syndrome and bipolar disorder: What should psychiatrists know?","volume":"18","author":"De Almeida","year":"2012","journal-title":"CNS Neurosci Ther."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/NDT.S98711","article-title":"Attitudes toward metabolic adverse events among patients with schizophrenia in Japan","volume":"12","author":"Sugawara","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0240","first-page":"20","article-title":"Risk factor assessment and counselling for 12 month reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study","volume":"44","author":"Guti\u00e9rrez-Rojas","year":"2016","journal-title":"Actas Esp Psiquiatr."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rpsm.2014.11.001","article-title":"Tendencias y necesidad cl\u00ednica de los principios \u00e9ticos","volume":"8","author":"Lolas-Stepke","year":"2015","journal-title":"Rev Psiquiatr Salud Ment (Barc)."},{"key":"10.1016\/j.rpsm.2016.09.003_bib0250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rpsm.2015.03.003","article-title":"La medicina personalizada aplicada a la salud mental: la psiquiatr\u00eda de precisi\u00f3n","volume":"8","author":"Vieta","year":"2015","journal-title":"Rev Psiquiatr Salud Ment (Barc)."}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188898911630091X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188898911630091X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:30:34Z","timestamp":1761823834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S188898911630091X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S188898911630091X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2016.09.003","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00edndrome metab\u00f3lico y antipsic\u00f3ticos at\u00edpicos. Posibilidad de predicci\u00f3n y control","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2016.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}